Announcements Trials

Browse Landscape

Status

Unknown 1 Completed 1

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Conditions

Neoplasms 1 Heart Diseases 1 Cardiotoxicity 1

Interventions

Surveys and Questionnaires 286 Blood Specimen Collection 145 Gene Expression Profiling 96 Interviews as Topic 83 Immunohistochemistry 78 Polymerase Chain Reaction 64 Surgical Procedures, Operative 62 Magnetic Resonance Spectroscopy 58 Microarray Analysis 55 Flow Cytometry 53 Radiotherapy 49 Amplified Fragment Length Polymorphism Analysis 48 Drug Therapy 46 Observation 45 Biopsy 42 Reverse Transcriptase Polymerase Chain Reaction 39 Bevacizumab 39 Data Collection 35 Sorafenib 29 Psychiatric Rehabilitation 29 Nivolumab 28 palbociclib 26 In Situ Hybridization, Fluorescence 26 Rituximab 25 Therapeutics 24 Neoadjuvant Therapy 24 Hepatectomy 24 Docetaxel 24 Colonoscopy 24 Sunitinib 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Observational × Immunomodulating Agents × Clear all

NCT03530215 2023-04-13

EROCA

Groupe Hospitalier Pitie-Salpetriere

500,000 enrolled

Heart Diseases, Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡